Great article about Abivax : what makes it a unique candidate to treat Covid-19
In addition to its exciting results in ulcerative colitis
In addition to its exciting results in ulcerative colitis, Abivax's ABX 464 has shown antiviral, anti-inflammatory and tissue repair properties in COVID-19 clinical trials.
Also to be discovered
Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests
Abivax, the French biotech embarking on tests of its lead experimental medicine for Covid-19, has turned away several suitors in recent months.
MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee
Medeor is among the 24 new funds qualified by the committee of institutional investors set up following the Tibi report.